Abstract
Lipoprotein [Lp(a)] is considered an independent risk factor for atherosclerosis. After its discovery in the last century, it returns to the view of scientific interest due to new possibilities of pharmacological influencing.
Levels above the 80. percentile, that is 50 mg/dl, were considered as hazardous values. However, the risk of cardiovascular disease appears to increase linearly with increasing levels.
Lp(a) and this limit cannot be taken arbitrarily. Previously published studies have not had consensus results on the causality of Lp(a) and cardiovascular risk levels.
Studies with niacin and cholesterol ester transfer protein (CETP) inhibitors, despite a decrease in Lp(a), did not show a decrease in cardiovascular risk. New hope in the therapy are PCSK-9 inhibitors and new antisense therapies, which certainly influence the level of Lp(a), but it is also necessary to prove an effect on the decrease of cardiovascular risk.